3rd Quarter - Report
ENGEL & NOVITT, LLP for BIOMARIN PHARMACEUTICAL INC.
Firm
Client
Income
$80,000
Expenses
—
What was lobbied
One issue area, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
Orphan Biologics under the Orphan Drug Act; seek amendment to health-care reform legislation to enable continued rare-disease research under the Orphan Drug Act for biologics as part of follow-on biologics pathway by establishing an Orphan Delta for Orphan Biologics to incentivize research and development of Orphan Biologics to treat rare diseases and conditions.
| Lobbyist | Covered position, as disclosed |
|---|---|
| JOHN M. ENGEL | N/A |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.